logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

MONALEESA-3: ribociclib linked to longer OS in HR+ HER2- advanced breast cancer

Survival was 28% longer with ribociclib+fulvestrant vs fulvestrant alone.